NASDAQ:CLLS - Cellectis Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$30.39 -0.34 (-1.11 %)
(As of 05/24/2018 04:00 PM ET)
Previous Close$30.73
Today's Range$30.01 - $30.76
52-Week Range$21.25 - $38.85
Volume77,700 shs
Average Volume270,813 shs
Market Capitalization$1.27 billion
P/E Ratio-10.93
Dividend YieldN/A
Beta1.88

About Cellectis (NASDAQ:CLLS)

Cellectis logoCellectis S.A., a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL). The company's products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-ALL. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc; Les Laboratoires Servier SAS; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Receive CLLS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CLLS
CUSIPN/A
Phone33-1-81-69-16-00

Debt

Debt-to-Equity RatioN/A
Current Ratio7.18
Quick Ratio7.17

Price-To-Earnings

Trailing P/E Ratio-10.93
Forward P/E Ratio-11.38
P/E GrowthN/A

Sales & Book Value

Annual Sales$33.72 million
Price / Sales37.49
Cash FlowN/A
Price / CashN/A
Book Value$6.65 per share
Price / Book4.57

Profitability

EPS (Most Recent Fiscal Year)($2.78)
Net Income$-99,360,000.00
Net Margins-337.45%
Return on Equity-37.45%
Return on Assets-31.83%

Miscellaneous

Employees122
Outstanding Shares41,600,000

Cellectis (NASDAQ:CLLS) Frequently Asked Questions

What is Cellectis' stock symbol?

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

How were Cellectis' earnings last quarter?

Cellectis (NASDAQ:CLLS) posted its quarterly earnings data on Monday, May, 7th. The biotechnology company reported ($0.71) EPS for the quarter, missing the Zacks' consensus estimate of ($0.70) by $0.01. The biotechnology company earned $8.07 million during the quarter, compared to analysts' expectations of $9.53 million. Cellectis had a negative net margin of 337.45% and a negative return on equity of 37.45%. View Cellectis' Earnings History.

When is Cellectis' next earnings date?

Cellectis is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Cellectis.

What price target have analysts set for CLLS?

6 brokers have issued 1 year price targets for Cellectis' shares. Their predictions range from $20.00 to $73.00. On average, they expect Cellectis' share price to reach $44.00 in the next twelve months. View Analyst Ratings for Cellectis.

Who are some of Cellectis' key competitors?

Who are Cellectis' key executives?

Cellectis' management team includes the folowing people:
  • Dr. André Choulika Ph.D., Co-Founder, Chairman and Chief Exec. Officer (Age 53)
  • Dr. David J. D. Sourdive Ph.D., Co-Founder, Exec. VP - Technical Operations and Director (Age 51)
  • Mr. Eric Dutang, Chief Financial Officer (Age 44)
  • Ms. Elsy Boglioli, Chief Operating Officer
  • Dr. Philippe Duchateau Ph.D., Chief Scientific Officer (Age 55)

When did Cellectis IPO?

(CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager.

Has Cellectis been receiving favorable news coverage?

Media coverage about CLLS stock has trended positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Cellectis earned a news sentiment score of 0.29 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 47.04 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Cellectis' major shareholders?

Cellectis' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Nexthera Capital LP (0.80%), BlackRock Inc. (0.30%), Point72 Asset Management L.P. (0.17%), JPMorgan Chase & Co. (0.16%), Bellevue Group AG (0.13%) and Jane Street Group LLC (0.12%). View Institutional Ownership Trends for Cellectis.

Which major investors are selling Cellectis stock?

CLLS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Citadel Advisors LLC and BlackRock Inc.. View Insider Buying and Selling for Cellectis.

Which major investors are buying Cellectis stock?

CLLS stock was purchased by a variety of institutional investors in the last quarter, including Nexthera Capital LP, Point72 Asset Management L.P., Jane Street Group LLC, JPMorgan Chase & Co., Bellevue Group AG, A.R.T. Advisors LLC, Wells Fargo & Company MN and Trellus Management Company LLC. View Insider Buying and Selling for Cellectis.

How do I buy shares of Cellectis?

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cellectis' stock price today?

One share of CLLS stock can currently be purchased for approximately $30.39.

How big of a company is Cellectis?

Cellectis has a market capitalization of $1.27 billion and generates $33.72 million in revenue each year. The biotechnology company earns $-99,360,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. Cellectis employs 122 workers across the globe.

How can I contact Cellectis?

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS LLE-DE-FRANCE I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]


MarketBeat Community Rating for Cellectis (CLLS)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  227 (Vote Outperform)
Underperform Votes:  119 (Vote Underperform)
Total Votes:  346
MarketBeat's community ratings are surveys of what our community members think about Cellectis and other stocks. Vote "Outperform" if you believe CLLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLLS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cellectis (NASDAQ:CLLS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Cellectis in the last 12 months. Their average twelve-month price target is $44.00, suggesting that the stock has a possible upside of 44.78%. The high price target for CLLS is $73.00 and the low price target for CLLS is $20.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.832.83
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $44.00$44.00$39.8333$39.8333
Price Target Upside: 44.78% upside25.36% upside39.13% upside19.80% upside

Cellectis (NASDAQ:CLLS) Consensus Price Target History

Price Target History for Cellectis (NASDAQ:CLLS)

Cellectis (NASDAQ:CLLS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/16/2018GuggenheimInitiated CoverageNeutral ➝ NeutralHighView Rating Details
3/14/2018NomuraBoost Price TargetBuy$73.00HighView Rating Details
12/28/2017OppenheimerReiterated RatingOutperform$40.00 ➝ $40.00LowView Rating Details
10/29/2017Jefferies GroupReiterated RatingBuy$47.00N/AView Rating Details
10/6/2017SunTrust BanksReiterated RatingHold$20.00N/AView Rating Details
9/5/2017Wells Fargo & CoReiterated RatingOutperform ➝ Outperform$33.00 ➝ $40.00HighView Rating Details
3/1/2017InstinetInitiated CoverageBuy ➝ Buy$49.00N/AView Rating Details
11/24/2016Piper Jaffray CompaniesSet Price TargetBuy$41.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Cellectis (NASDAQ:CLLS) Earnings History and Estimates Chart

Earnings by Quarter for Cellectis (NASDAQ:CLLS)

Cellectis (NASDAQ:CLLS) Earnings Estimates

2018 EPS Consensus Estimate: ($2.80)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.71)($0.59)($0.65)
Q2 20182($0.72)($0.68)($0.70)
Q3 20182($0.76)($0.68)($0.72)
Q4 20182($0.78)($0.67)($0.73)

Cellectis (NASDAQ CLLS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2018        
5/7/2018Q1($0.6980)($0.71)$9.53 million$8.07 millionViewN/AView Earnings Details
3/12/2018Q4 2017($0.64)($0.76)$10.10 million$6.91 millionViewN/AView Earnings Details
11/13/2017Q3 2017($0.57)($0.73)$10.56 million$7.25 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.59)($0.74)$10.30 million$8.96 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.56)($0.56)$9.52 million$10.30 millionViewN/AView Earnings Details
3/6/2017Q4 2016($0.34)($0.38)$9.65 million$13.02 millionViewN/AView Earnings Details
11/22/2016Q3 2016($0.90)($0.40)$9.74 million$12.62 millionViewN/AView Earnings Details
9/8/2016Q2 2016($0.64)($0.20)$8.02 million$20.49 millionViewN/AView Earnings Details
5/11/2016Q1 2016($0.35)($0.92)$7.78 million$10.48 millionViewN/AView Earnings Details
3/14/2016Q4 2015($0.06)$0.25$5.72 million$31.97 millionViewN/AView Earnings Details
11/16/2015Q215($0.43)($0.40)$1.23 million$11.10 millionViewN/AView Earnings Details
9/8/2015Q2 2015($0.64)($0.70)$2.37 million$8.85 millionViewN/AView Earnings Details
6/9/2015Q1 2015$0.26$10.29 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Cellectis (NASDAQ:CLLS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Cellectis (NASDAQ CLLS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 16.41%
Institutional Ownership Percentage: 16.75%
Insider Trading History for Cellectis (NASDAQ:CLLS)
Institutional Ownership by Quarter for Cellectis (NASDAQ:CLLS)

Cellectis (NASDAQ CLLS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Cellectis (NASDAQ CLLS) News Headlines

Source:
DateHeadline
BRIEF-Cellectis Announces Approval Of Amendment To Protocol For UCART123 Phase 1 Clinical TrialBRIEF-Cellectis Announces Approval Of Amendment To Protocol For UCART123 Phase 1 Clinical Trial
www.reuters.com - May 23 at 8:37 AM
INSERTING and REPLACING: Approval of UCART123 Amendment in AML to Accelerate Clinical DevelopmentINSERTING and REPLACING: Approval of UCART123 Amendment in AML to Accelerate Clinical Development
finance.yahoo.com - May 23 at 8:37 AM
Cellectis: Approval of UCART123 Amendment in AML to Accelerate Clinical DevelopmentCellectis: Approval of UCART123 Amendment in AML to Accelerate Clinical Development
www.businesswire.com - May 22 at 4:54 PM
Cellectis SA : Calyxt Announces Successful Closing of $60.9 Million Public OfferingCellectis SA : Calyxt Announces Successful Closing of $60.9 Million Public Offering
www.businesswire.com - May 22 at 4:54 PM
Cellectis: Approval of UCART123 Amendment in AML to Accelerate Clinical DevelopmentCellectis: Approval of UCART123 Amendment in AML to Accelerate Clinical Development
finance.yahoo.com - May 22 at 4:54 PM
Cellectis: Will Focus On Universal CAR-T Payoff?Cellectis: Will Focus On Universal CAR-T Payoff?
seekingalpha.com - May 21 at 4:55 PM
Cellectis SA: Calyxt Announces Full Exercise of Underwriters Option to Purchase Additional SharesCellectis SA: Calyxt Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
www.businesswire.com - May 21 at 8:38 AM
Cellectis S.A.: Calyxt Announces Full Exercise of Underwriters’ Option to Purchase Additional SharesCellectis S.A.: Calyxt Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - May 21 at 8:38 AM
Zacks: Analysts Anticipate Cellectis (CLLS) Will Announce Quarterly Sales of $9.43 MillionZacks: Analysts Anticipate Cellectis (CLLS) Will Announce Quarterly Sales of $9.43 Million
www.americanbankingnews.com - May 20 at 3:04 AM
Calyxt (CLXT) Prices 3.6M Share Upsized Follow-On Offering at $15/ShCalyxt (CLXT) Prices 3.6M Share Upsized Follow-On Offering at $15/Sh
www.streetinsider.com - May 18 at 5:26 PM
-$0.34 Earnings Per Share Expected for Cellectis (CLLS) This Quarter-$0.34 Earnings Per Share Expected for Cellectis (CLLS) This Quarter
www.americanbankingnews.com - May 18 at 1:42 PM
Calyxt Announces Launch of Proposed Follow-On OfferingCalyxt Announces Launch of Proposed Follow-On Offering
finance.yahoo.com - May 16 at 8:53 AM
Cellectis (CLLS) Upgraded at Zacks Investment ResearchCellectis (CLLS) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 15 at 8:15 PM
Genomic Medicine: Catch The Gene Therapy WaveGenomic Medicine: Catch The Gene Therapy Wave
seekingalpha.com - May 14 at 5:03 PM
Cellectis to Present Data at the 2018 ASGCT Annual MeetingCellectis to Present Data at the 2018 ASGCT Annual Meeting
finance.yahoo.com - May 10 at 5:26 PM
Wired News - Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration with MSK to Develop Next-Generation CAR T TechnologiesWired News - Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration with MSK to Develop Next-Generation CAR T Technologies
finance.yahoo.com - May 10 at 8:52 AM
Cellectis (CLLS) Receives Average Recommendation of "Hold" from BrokeragesCellectis (CLLS) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 10 at 1:32 AM
Cellectis (CLLS) Downgraded by BidaskClub to "Sell"Cellectis (CLLS) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - May 9 at 6:47 PM
Cellectis (CLLS) Posts  Earnings ResultsCellectis (CLLS) Posts Earnings Results
www.americanbankingnews.com - May 8 at 9:34 AM
Quarter 2018 Financial ResultsQuarter 2018 Financial Results
www.businesswire.com - May 7 at 5:16 PM
Cellectis Reports 1st Quarter 2018 Financial ResultsCellectis Reports 1st Quarter 2018 Financial Results
finance.yahoo.com - May 7 at 5:16 PM
Zacks: Analysts Anticipate Cellectis (CLLS) Will Post Quarterly Sales of $9.53 MillionZacks: Analysts Anticipate Cellectis (CLLS) Will Post Quarterly Sales of $9.53 Million
www.americanbankingnews.com - May 3 at 5:54 AM
Cellectis Files IND for UCART22 in Acute Lymphoblastic Leukemia (B-ALL)Cellectis Files IND for UCART22 in Acute Lymphoblastic Leukemia (B-ALL)
finance.yahoo.com - May 2 at 5:12 PM
Harvards Wyss Institute partners with Cellectis to recode the human genomeHarvard's Wyss Institute partners with Cellectis to recode the human genome
www.prnewswire.com - May 1 at 8:50 AM
George Church, CRISPR Pioneer, Embraces Alternative Tech In Project To Recode A Human GenomeGeorge Church, CRISPR Pioneer, Embraces Alternative Tech In Project To Recode A Human Genome
finance.yahoo.com - May 1 at 8:50 AM
Harvard’s Wyss Institute Partners with Cellectis to Recode the Human GenomeHarvard’s Wyss Institute Partners with Cellectis to Recode the Human Genome
finance.yahoo.com - May 1 at 8:50 AM
-$0.66 EPS Expected for Cellectis (CLLS) This Quarter-$0.66 EPS Expected for Cellectis (CLLS) This Quarter
www.americanbankingnews.com - May 1 at 1:10 AM
Cellectis (CLLS) Lowered to "Hold" at ValuEngineCellectis (CLLS) Lowered to "Hold" at ValuEngine
www.americanbankingnews.com - April 27 at 1:36 PM
Should Cellectis SA.’s (EPA:ALCLS) Recent Earnings Decline Worry You?Should Cellectis SA.’s (EPA:ALCLS) Recent Earnings Decline Worry You?
finance.yahoo.com - April 18 at 8:43 AM
Cellectis (CLLS) Downgraded by BidaskClub to "Hold"Cellectis (CLLS) Downgraded by BidaskClub to "Hold"
www.americanbankingnews.com - April 16 at 10:55 AM
Zacks: Analysts Anticipate Cellectis (CLLS) Will Announce Quarterly Sales of $9.53 MillionZacks: Analysts Anticipate Cellectis (CLLS) Will Announce Quarterly Sales of $9.53 Million
www.americanbankingnews.com - April 16 at 4:58 AM
Cellectis (CLLS) Given Average Rating of "Hold" by AnalystsCellectis (CLLS) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - April 15 at 1:39 AM
Cellectis (CLLS) Stock Rating Lowered by BidaskClubCellectis (CLLS) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 14 at 6:22 PM
 Brokerages Anticipate Cellectis (CLLS) Will Post Earnings of -$0.66 Per Share Brokerages Anticipate Cellectis (CLLS) Will Post Earnings of -$0.66 Per Share
www.americanbankingnews.com - April 14 at 3:17 AM
What Should We Expect From Cellectis SA.’s (NASDAQ:CLLS) Earnings Over The Next Few Years?What Should We Expect From Cellectis SA.’s (NASDAQ:CLLS) Earnings Over The Next Few Years?
finance.yahoo.com - April 13 at 8:55 AM
Cellectis Announces Closing of Follow-On OfferingCellectis Announces Closing of Follow-On Offering
finance.yahoo.com - April 10 at 5:09 PM
Cellectis (CLLS) Earns Buy Rating from Jefferies GroupCellectis (CLLS) Earns Buy Rating from Jefferies Group
www.americanbankingnews.com - April 8 at 8:06 PM
Is Cellectis SA Stock a Buy Now?Is Cellectis SA Stock a Buy Now?
finance.yahoo.com - April 7 at 9:04 AM
Can Been-There Biotech Entrepreneur Arie Belldegrun Do It Yet Again?Can Been-There Biotech Entrepreneur Arie Belldegrun Do It Yet Again?
finance.yahoo.com - April 6 at 8:55 AM
Cellectis: Monthly Information on Share Capital and Company Voting RightsCellectis: Monthly Information on Share Capital and Company Voting Rights
www.businesswire.com - April 5 at 4:59 PM
Why Micron Technology, Mechel, and Cellectis Slumped TodayWhy Micron Technology, Mechel, and Cellectis Slumped Today
finance.yahoo.com - April 5 at 4:59 PM
Cellectis (CLLS) Announces Launch of $175M Follow-On OfferingCellectis (CLLS) Announces Launch of $175M Follow-On Offering
www.streetinsider.com - April 5 at 10:47 AM
Cellectis down 2% premarket on pricing of follow-on offeringCellectis down 2% premarket on pricing of follow-on offering
seekingalpha.com - April 5 at 10:47 AM
Cellectis (CLLS) Upgraded to Buy at ValuEngineCellectis (CLLS) Upgraded to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 5:52 PM
Cellectis to continue CAR T collaboration with Allogene; shares up 18%Cellectis to continue CAR T collaboration with Allogene; shares up 18%
seekingalpha.com - April 3 at 5:09 PM
Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate ...Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate ...
www.businesswire.com - April 3 at 8:53 AM
Cellectis, Allogene To Continue Strategic Cancer Immunotherapy CollaborationCellectis, Allogene To Continue Strategic Cancer Immunotherapy Collaboration
www.nasdaq.com - April 3 at 8:53 AM
Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T TherapiesCellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies
finance.yahoo.com - April 3 at 8:53 AM
Cellectis (CLLS) Stock Rating Upgraded by BidaskClubCellectis (CLLS) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 30 at 6:14 PM
Zacks: Analysts Anticipate Cellectis SA (CLLS) Will Announce Earnings of -$0.66 Per ShareZacks: Analysts Anticipate Cellectis SA (CLLS) Will Announce Earnings of -$0.66 Per Share
www.americanbankingnews.com - March 28 at 3:08 AM

SEC Filings

Cellectis (NASDAQ:CLLS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cellectis (NASDAQ:CLLS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cellectis (NASDAQ CLLS) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.